1701 - A case of Carpal Tunnel Syndrome after BPC 157 injections to hasten recovery

Thursday, February 19, 2026

5:00 PM - 6:30 PM AST

Presenting Author(s)

AD

Alaba Danagogo, MD

Resident
Northwell Plainview Hospital
Plainview, New York, United States

Co-Author(s)

JL

Jiani Liang, MD

Resident
Northwell Plainview Hospital
Plainview, New York, United States
SD

Stuti Dixit, DO

Resident
Northwell Plainview Hospital
Plainview, New York, United States
NV

Nicole Volino, DO

Resident
Northwell Plainview Hospital
Plainview, New York, United States

Corresponding Author(s)

JM

Joseph Muraca, DO

Resident
Northwell Plainview Hospital
Plainview, New York, United States

Submitter(s)

AD

Alaba Danagogo, MD

Northwell Plainview Hospital
Westbury, New York, United States

Case Diagnosis: Carpal Tunnel Syndrome (CTS) is the most common focal neuropathy in adults, resulting from compression of the median nerve due to high pressures within the carpal tunnel. It is signaled by pain, numbness and tingling in the first 3 fingers and half of the fourth finger, with variations in pain radiating through the wrists, forearms or elbows. In this case, the patient exhibits signs of CTS and systemic symptoms of transaminitis after intramuscular injection of the polypeptide Body Protection Compound (BPC) 157.

Case Description: A 40-year-old male with hypertension and recent motorcycle accidents presents with bilateral forearm pain, swelling, and redness after injecting BPC 157 into both forearms a month prior. He reports severe stinging pain, limited wrist motion, numbness and tingling in his thumbs and index fingers, and draining pustules at the injection sites. Over the past week, he developed fatigue and generalized abdominal pain. Workup revealed transaminitis, hepatosplenomegaly, and no infectious pathogen.

Discussions: A diagnosis of CTS due to an immune-mediated inflammatory response was proposed. BPC 157 is a stable human gastric juice pentadecapeptide derivative which is suggested to have numerous therapeutic benefits including GI tract wound healing, ligament and tissue recovery in various models. However, it has only been tested in rodents with scarce evidence regarding appropriate dosing, toxicity profiles and effectiveness in humans seeking regenerative medicine after critical injuries. This case suggests the peptide influences liver function in humans, leading to progressive transaminitis during hepatic clearance.

Conclusions: Patients often seek methods for promoting quick regeneration after severe injuries. With the rising popularity of BPC 157 on the black market, rehabilitation patients are vulnerable to risks associated with improper and off-label administration of this peptide. Physiatrists should be aware of the potential conditions and side effects arising from BPC 157 injections to aid appropriate recognition and management.